Page last updated: 2024-08-26

wr 1065 and Neoplasms

wr 1065 has been researched along with Neoplasms in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (28.57)	18.7374
1990's	2 (28.57)	18.2507
2000's	3 (42.86)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bykov, VJ; Selivanova, G; Wiman, KG	1
Koukourakis, MI	1
Capizzi, R	1
Capizzi, RL	1
Baruchel, S; Fouladi, M; Gammon, J; Grant, R; Greenberg, ML; Klein, J; Koren, G; Stempak, D	1
Grdina, DJ; Nagy, B; Sigdestad, CP	1
Bonner, HS; Glover, DJ; Kligerman, MM; Norfleet, AL; Shaw, LM; Turrisi, AT; Weiler, C	1

Reviews

5 review(s) available for wr 1065 and Neoplasms

Article	Year
Small molecules that reactivate mutant p53. European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:13 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ellipticines; Gene Expression Regulation, Neoplastic; Genes, p53; Genetic Therapy; Humans; Mercaptoethylamines; Molecular Chaperones; Mutation; Neoplasms; Pyrimidines	2003
Amifostine: is there evidence of tumor protection? Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dogs; Drug Evaluation, Preclinical; Humans; Mercaptoethylamines; Models, Animal; Neoplasms; Organoplatinum Compounds; Radiation Injuries; Radiation-Protective Agents; Rats; Sarcoma	2003
Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Seminars in oncology, 1996, Volume: 23, Issue:4 Suppl 8 Topics: Amifostine; Animals; Antineoplastic Agents; Cells; Combined Modality Therapy; Humans; Mercaptoethylamines; Neoplasms; Premedication	1996
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Seminars in oncology, 1999, Volume: 26, Issue:2 Suppl 7 Topics: Amifostine; Animals; Antineoplastic Agents; Cytoprotection; Drug Evaluation, Preclinical; Humans; Mercaptoethylamines; Neoplasms; Neoplasms, Experimental; Prodrugs; Protective Agents; Radiation-Protective Agents; Tumor Cells, Cultured	1999
Radioprotectors in treatment therapy to reduce risk in secondary tumor induction. Pharmacology & therapeutics, 1988, Volume: 39, Issue:1-3 Topics: Amifostine; Animals; Cell Transformation, Neoplastic; Humans; Mercaptoethylamines; Neoplasms; Neoplasms, Radiation-Induced; Radiation-Protective Agents	1988

Trials

1 trial(s) available for wr 1065 and Neoplasms

Article	Year
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer, 2001, Aug-15, Volume: 92, Issue:4 Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Male; Mercaptoethylamines; Neoplasms; Treatment Failure	2001

Article

Year

Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.

Cancer, 2001, Aug-15, Volume: 92, Issue:4

Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Male; Mercaptoethylamines; Neoplasms; Treatment Failure

2001

Other Studies

1 other study(ies) available for wr 1065 and Neoplasms

Article	Year
Human pharmacokinetics of WR-2721. International journal of radiation oncology, biology, physics, 1986, Volume: 12, Issue:8 Topics: Amifostine; Humans; Kinetics; Mercaptoethylamines; Neoplasms; Organothiophosphorus Compounds; Radiation-Protective Agents; Tissue Distribution	1986